Resource Development Core

资源开发核心

• 批准号: 10746571
• 负责人: Javier A. Neyra
• 金额: $ 14.65万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10746571
• 关键词: Acceleration; Acute Renal Failure with Renal Papillary Necrosis; Address; Adoption; Anatomy; Animal Model; Area; Artificial Intelligence; Big Data; Biologic Characteristic; Biological; Biological Assay; Biology; Caring; Classification; Clinical; Clinical Research; Data; Data Analyses; Development; Disease; Electronic Health Record; Etiology; Evaluation; Feedback; Focus Groups; Future; Goals; Heterogeneity; Image; Incubated; Incubators; Individual; Infrastructure; Institution; Interview; Kidney; Leadership; Learning; Magnetic Resonance Imaging; Methodology; Methods; Microfluidics; Molecular; Pathway interactions; Patients; Peptides; Persons; Phenotype; Physiology; Policies; Positron-Emission Tomography; Procedures; Protocols documentation; Reproducibility; Research; Research Methodology; Research Personnel; Resolution; Resource Development; Resources; Risk; Services; Sustainable Development; System; Technology; Testing; Thinking; Time; Tissues; Translational Research; Validation; biomedical resource; data harmonization; data management; digital; federated learning; health inequalities; high standard; implementation science; improved; in vivo imaging; innovation; metabolomics; multi-task learning; new technology; novel; novel therapeutics; patient oriented; phenotypic data; pre-clinical; pre-clinical research; preclinical imaging; research clinical testing; response; small molecule; tool; translational applications; treatment effect

Innovations to mitigate the global burden of acute kidney injury (AKI) require catalyzers that network investigators and provide them with resources that facilitate discovery, translation and implementation science to impact bedside care, improve policy and dismantle health inequalities. The overarching objective of the Resource Development Core is to incubate novel and strategic approaches to continuously support AKI research across a diverse universe of investigators in the O'Brien Kidney Consortium. This Core will provide a dynamic resource and platform to develop, test and refine innovations that could accelerate pre-clinical and clinical research and then can be offered as part of the Biomedical Resource Cores. The initial focus of this Core will be centered in advanced and quantitative AKI biological characterization and big data analyses. In the pre-clinical area, novel analytical approaches in metabolomics and molecular and functional in vivo imaging will be incubated to probe unique biological characteristics of disease development. In the clinical area, tools for multi-institutional Electronic Health Record (EHR) data management and harmonization and a novel federated learning platform to evaluate Artificial Intelligence (AI)-based tools will be developed. These development areas will be frequently evaluated to assure that the selected tools to be refined or developed are relevant to patients and investigators, and use the most advanced technologies to maintain high standards of validation, reproducibility and transferability tailoring the growing investigator's needs with a pathway to be offered in the Biomedical Cores in the future. To continue to drive innovations in AKI research, the following Specific Aims are proposed. In Aim 1, we will develop an incubator for novel technologies to support pre-clinical research in AKI. Specifically, in Aim 1A, we will develop tools for the examination of the disturbed distribution of small molecules and peptides in AKI. We will develop novel microfluidic methods aimed at high resolution molecular cartography in kidney tissue. In Aim 1B, we will develop molecular and functional kidney-specific imaging and image-analysis approaches in pre-clinical animal models of AKI. Probing for longitudinal evaluations of tissue- scale biological changes with translational positron emission tomography (PET) and magnetic resonance imaging (MRI) will elucidate key molecular, functional, and anatomical alterations during AKI development and in response to novel therapeutics. In Aim 2, we will develop an incubator for digital workspace technologies to support EHR data analyses in AKI. This will include enhancements in existing collaborative digital workspaces to support EHR data management and harmonization (Aim 2A) and the development of a novel federated multi- task learning platform to evaluate AI-based tools (Aim 2B). These aims are forward-thinking to enable novel methodologies to better understand the pathobiology and heterogeneity of AKI.

减轻急性肾损伤（阿基）全球负担的创新需要催化剂， 研究人员，并为他们提供资源，促进发现，翻译和实施科学 影响床边护理，改善政策，消除健康不平等。的首要目标 资源开发核心是孵化新的战略方法，以持续支持阿基 在奥布莱恩肾脏协会的不同领域的研究人员进行的研究。该核心将提供一个 动态资源和平台，以开发，测试和完善创新，可以加速临床前和 临床研究，然后可以作为生物医学资源核心的一部分提供。最初的焦点是 核心将集中在先进的和定量的阿基生物表征和大数据分析。在 在临床前领域，代谢组学和分子及功能体内成像的新分析方法将 进行孵育，以探测疾病发展的独特生物学特征。在临床领域， 多机构电子健康记录（EHR）数据管理和协调以及一种新的联合 将开发一个评估人工智能（AI）工具的学习平台。这些发展领域 将经常进行评估，以确保所选工具的完善或开发与患者相关 和调查人员，并使用最先进的技术，以保持高标准的验证， 可重复性和可转移性，以满足日益增长的研究者的需求，并提供一个途径， 未来的生物医学核心。为了继续推动阿基研究的创新，以下具体目标 被提议。在目标1中，我们将开发新技术孵化器，以支持以下方面的临床前研究： 阿基具体而言，在目标1A中，我们将开发用于检查小的干扰分布的工具。 分子和肽类。我们将开发新的微流控方法， 肾脏组织中的绘图。在目标1B中，我们将开发分子和功能性肾脏特异性成像， 阿基临床前动物模型中的图像分析方法。探索组织的纵向评估- 平移正电子发射断层扫描（PET）和磁共振的大规模生物学变化 MRI将阐明阿基发展过程中的关键分子、功能和解剖学改变， 对新疗法的反应。在目标2中，我们将开发数字工作空间技术的孵化器， 支持阿基中的EHR数据分析。这将包括增强现有的协作数字化 支持EHR数据管理和协调（Aim 2A）以及开发一种新型的联邦多 任务学习平台，以评估基于AI的工具（目标2B）。这些目标具有前瞻性， 更好地了解阿基的病理生物学和异质性的方法。